|Bid||83.55 x 1000|
|Ask||83.88 x 900|
|Day's Range||83.34 - 84.29|
|52 Week Range||79.09 - 95.17|
|Beta (5Y Monthly)||0.48|
|PE Ratio (TTM)||7.87|
|Forward Dividend & Yield||3.33 (3.95%)|
|Ex-Dividend Date||Mar 08, 2022|
|1y Target Est||104.40|
Subscribe to Yahoo Finance Plus to view Fair Value for NVS
Celldex took aim at Roche and Novartis' blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.